Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r

an antagonism and chronic obstructive pulmonary disease technology, applied in the direction of antibacterial agents, drug compositions, antibody medical ingredients, etc., can solve the problems of affecting the health and quality of life of subjects, severe and increasing global health problems, and prior exacerbation is an independent risk factor

Inactive Publication Date: 2017-11-16
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is discussing a method for reducing the symptoms of acute exacerbations in subjects with chronic obstructive pulmonary disease (COPD). An acute exacerbation is a worsening of the symptoms of COPD that is sudden and beyond normal variations. The method involves reducing the frequency, severity, or duration of symptoms such as dyspnea, increased sputum production, coughing, wheezing, chest tightness, and fatigue. The text mentions that viral and bacterial infections, as well as air pollution, are common causes of acute exacerbations, and that the method can help alleviate symptoms associated with them. Ultimately, the technical effect of this patent is to provide a method for reducing the symptoms of acute exacerbations in subjects with COPD.

Problems solved by technology

Chronic obstructive pulmonary disease (COPD) represents a severe and increasing global health problem.
Acute exacerbations of COPD greatly affect the health and quality of life of subjects with COPD.
Multiple studies have also shown that prior exacerbation is an independent risk factor for future hospitalization for COPD.
However up to now, there is no method for the treatment of acute exacerbation of COPD.
However the role of IL-20 cytokines has never been investigated in acute exacerbation of COPD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r
  • Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r
  • Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r

Examples

Experimental program
Comparison scheme
Effect test

example

[0060]Introduction:

[0061]Bacterial complications are a common feature during a wide variety of lung inflammatory disorders such as COPD. In patients with COPD, acute exacerbation is mostly associated with bacterial infections frequently due to Haemophilus influenzae and Streptococcus pneumoniae. These infections provoked a strong inflammatory reaction characterized by neutrophil recruitment, increased production of pro-inflammatory cytokines and accelerated the progression of the disease. Appropriate models are needed to better define mechanisms responsible for bacterial susceptibility during the exacerbation of COPD. We have already developed a murine model of COPD by chronic exposure to cigarette smoke (CS) during 12 weeks. This exposure strongly modifies the innate immune response in the lung and the activation of invariant natural killer T (iNKT) cells (Pichavant M et al., Mucosal Immunol, 2014). To better define the mechanisms responsible for bacterial susceptibility, we have n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of IL-20 cytokines.

Description

[0001]The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease.BACKGROUND OF THE INVENTION[0002]Chronic obstructive pulmonary disease (COPD) represents a severe and increasing global health problem. By 2020, COPD will have increased from 6th (as it is currently) to the 3rd most common cause of death worldwide. In the United States, COPD is believed to account for up to 120,000 deaths per year. The clinical course of COPD is characterized by chronic disability, with intermittent, acute exacerbations which may be triggered by a variety of stimuli including exposure to pathogens, inhaled irritants (e.g., cigarette smoke), allergens, or pollutants. “Acute exacerbation” refers to worsening of a subject's COPD symptoms from his or her usual state that is beyond normal day-to-day variations, and is acute in onset. Acute exacerbations of COPD greatly affect the health and quality of life of subj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/24C07K16/28A61K39/00
CPCC07K16/244C07K16/2866C07K16/2887A61K39/00A61K2039/505C07K2317/76A61K31/7088A61P11/00A61P31/04A61P31/12A61P43/00
Inventor GOSSET, PHILIPPEPICHAVANT, MURIELPEREZ-CRUZ, MAGDIELKONE, BACHIROU
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com